Transplantation

1-10 of 10

• 

  RestartResume

  Real-World Outcomes with Axatilimab in cGVHD

  RestartResume

  Real-World Outcomes with Axatilimab in cGVHD

  Project Oncology®

  Real-World Outcomes with Axatilimab in cGVHD

  Brian P. McDonough, MD, FAAFP; Hana Safah, MD

  • 

    

    Brian P. McDonough, MD, FAAFP

  • 

    

    Hana Safah, MD

• 

  RestartResume

  Axatilimab’s Impact on cGVHD and Associated BOS

  RestartResume

  Axatilimab’s Impact on cGVHD and Associated BOS

  Project Oncology®

  Axatilimab’s Impact on cGVHD and Associated BOS

  Charles Turck, PharmD, BCPS, BCCCP; Amandeep Salhotra, MD

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Amandeep Salhotra, MD

• 

  RestartResume

  Interpreting and Applying cGVHD Clinical Trial Data

  RestartResume

  Interpreting and Applying cGVHD Clinical Trial Data

  Project Oncology®

  Interpreting and Applying cGVHD Clinical Trial Data

  Charles Turck, PharmD, BCPS, BCCCP; Christopher Graham, MD

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Christopher Graham, MD

• 

  RestartResume

  Optimizing cGVHD Treatment Decisions in the Second- and Third-Line Settings

  RestartResume

  Optimizing cGVHD Treatment Decisions in the Second- and Third-Line Settings

  Project Oncology®

  Optimizing cGVHD Treatment Decisions in the Second- and Third-Line Settings

  Charles Turck, PharmD, BCPS, BCCCP; Stephanie Gregory, CNP

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Stephanie Gregory, CNP

• 

  RestartResume

  Real-World Strategies for Complex cGVHD Treatment Decisions

  RestartResume

  Real-World Strategies for Complex cGVHD Treatment Decisions

  Project Oncology®

  Real-World Strategies for Complex cGVHD Treatment Decisions

  Brian P. McDonough, MD, FAAFP; Doris M. Ponce, MD, MS

  • 

    

    Brian P. McDonough, MD, FAAFP

  • 

    

    Doris M. Ponce, MD, MS

• 

  RestartResume

  Making Mechanism-Based Treatment Decisions in cGVHD

  RestartResume

  Making Mechanism-Based Treatment Decisions in cGVHD

  Project Oncology®

  Making Mechanism-Based Treatment Decisions in cGVHD

  Brian P. McDonough, MD, FAAFP; Alicia Lieberman, MD, MS

  • 

    

    Brian P. McDonough, MD, FAAFP

  • 

    

    Alicia Lieberman, MD, MS

• 

  RestartResume

  Early Detection Shapes Outcomes in Post-Transplant Lung Cancer

  RestartResume

  Early Detection Shapes Outcomes in Post-Transplant Lung Cancer

  Project Oncology®

  Early Detection Shapes Outcomes in Post-Transplant Lung Cancer

• 

  RestartResume

  Advancing Relapse Prediction in Pediatric AML Through Genomic MRD

  RestartResume

  Advancing Relapse Prediction in Pediatric AML Through Genomic MRD

  On the Frontlines of AML/ALL

  Advancing Relapse Prediction in Pediatric AML Through Genomic MRD

  Ryan Quigley; Amanda Winters, MD, PhD

  • 

    

    Ryan Quigley

  • 

    

    Amanda Winters, MD, PhD

• 

  RestartResume

  Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease

  RestartResume

  Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease

  Clinician's Roundtable

  Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease

• 

  RestartResume

  Hepatocellular Carcinoma: Clinical Priorities from Detection to Liver Transplantation

  RestartResume

  Hepatocellular Carcinoma: Clinical Priorities from Detection to Liver Transplantation

  Medical Breakthroughs from Penn Medicine

  Hepatocellular Carcinoma: Clinical Priorities from Detection to Liver Transplantation

  Barnett Mennen, MD; Maarouf Hoteit, MD

  • 

    

    Barnett Mennen, MD

  • 

    

    Maarouf Hoteit, MD